ArticleBMC endocrine disorders2025
Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines recommend discontinuing mineralocorticoid receptor antagonists (MRA) at least 4 weeks before adrenal venous sampling (AVS) in primary aldosteronism (PA) to avoid interference with the lateralization index (LI). However, discontinuing MRA can cause hypertension and hypokalemia. This study aimed to evaluate the impact of continuing MRA use prior to AVS.
methodsA 5-year retrospective cohort study of patients aged ≥ 18 with PA who underwent successful AVS was conducted. Patients were divided into two groups: those who continued MRA during AVS and those who discontinued it for at least 4 weeks prior. Outcomes included differences in LI, plasma renin activity (PRA) levels before AVS, and post-adrenalectomy outcomes. Linear regression analysis clustered by subtypes of PA was used to adjust for confounders.
resultsA total of 66 patients were included, with 30 (45.5%) in the continued MRA group and 36 (54.5%) in the discontinued MRA group. After adjustment for confounders, PRA levels before AVS showed no significant difference between the groups (β-coefficient 0.5, 95% CI -2.0 to 3.0; p = 0.239) and there was no significant difference in the LI between the continued and discontinued MRA groups (β-coefficient 7.9, 95% CI -27.8 to 43.7; p = 0.216). Clinical and biochemical success after unilateral adrenalectomy were similar between the two groups (p = 0.141 and p = 0.596, respectively).
conclusionContinuing MRA prior to AVS did not appear to affect the interpretation of lateralization and may be a reasonable option for patients at high risk of complications from MRA withdrawal. Further prospective studies are needed to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.